secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-08-18T21:00:14+00:00
Accession:  0001193125-26-355664
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Amgen terminates Crohn's disease collaboration with TScan; effective Nov 10, 2026
--------------------------------------------------------------------------------

- Amgen gave notice Aug 12, 2026 to terminate Research Collaboration and License Agreement; effective Nov 10, 2026.
- No early termination penalty; TScan received $30M upfront in 2023, potential milestones over $500M now unlikely.
- Collaboration used TScan's target discovery platform for Crohn's disease; Amgen had exclusive worldwide license.
- TScan expects no future milestone/royalty payments unless Amgen continues to exploit product candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/0001193125-26-355664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/d143845d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-355664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer